drugset / Trial / NCT03927495
KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2
Unknown
100 enrolled
Shanghai Chest Hospital
First Affiliated Hospital of Suzhou Medical College · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
Timeline
- Start
- 2019-05-22
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |